|
|
|
|
| LEADER |
03323nam a22004935i 4500 |
| 001 |
8318 |
| 003 |
DE-He213 |
| 005 |
20130725205535.0 |
| 007 |
cr nn 008mamaa |
| 008 |
110413s2010 xxu| s |||| 0|eng d |
| 020 |
# |
# |
|a 9780387766430
|9 978-0-387-76643-0
|
| 024 |
7 |
# |
|a 10.1007/978-0-387-76643-0
|2 doi
|
| 050 |
# |
4 |
|a RC321-580
|
| 072 |
# |
7 |
|a PSAN
|2 bicssc
|
| 072 |
# |
7 |
|a MED057000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 612.8
|2 23
|
| 100 |
1 |
# |
|a Shire, Steven J.
|e editor.
|
| 245 |
1 |
0 |
|a Current Trends in Monoclonal Antibody Development and Manufacturing
|c edited by Steven J. Shire, Wayne Gombotz, Karoline Bechtold-Peters, James Andya.
|h [electronic resource] /
|
| 264 |
# |
1 |
|a New York, NY :
|b Springer New York :
|b Imprint: Springer,
|c 2010.
|
| 300 |
# |
# |
|a XIV, 354 p.
|b online resource.
|
| 336 |
# |
# |
|a text
|b txt
|2 rdacontent
|
| 337 |
# |
# |
|a computer
|b c
|2 rdamedia
|
| 338 |
# |
# |
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
# |
# |
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
# |
|a Biotechnology: Pharmaceutical Aspects ;
|v XI
|
| 505 |
0 |
# |
|a Introduction -- Design of Therapeutic Monoclonal Antibodies -- Manufacturing of Monoclonal Antibodies/Expression and Production of Monoclonal Antibodies -- Manufacturing of Monoclonal Antibodies/ Recovery and Purification of Bulk Drug Substance -- Formulation and Delivery Challenges -- Analytics and Specification Setting of MAbs -- Pharmacokinetics of Mabs -- Clinics and Toxicology -- Future Trends.
|
| 520 |
# |
# |
|a Monoclonal antibodies represent one of the fastest growing areas of new drug development within the pharmaceutical industry. Several blockbuster products have been approved over the past several years including Rituxan, Remicade, Avastin, Humira, and Herceptin. In addition, over 300 new drugs are currently in clinical trials. With both large, established biotechnology companies and small start-ups involved in the development of this important class of molecules, monoclonal antibodies products will become increasingly prevalent over the next decade. Recently the regulatory review of monoclonal antibodies has been moved from Center for Biologics and Research to the Center for Drug Evaluation and Research (CDER) division of the US Food and Drug Administration. It is anticipated that CDER will expect a certain minimal amount of data to be provided as more of these products move through the regulatory pipeline. Current Trends in Monoclonal Antibody Development and Manufacturing will provide readers with an understanding of what is currently being done in the industry to develop, manufacture, and release monoclonal antibody products and what will be required for a successful regulatory submission.
|
| 650 |
# |
0 |
|a Medicine.
|
| 650 |
# |
0 |
|a Neurosciences.
|
| 650 |
# |
0 |
|a Toxicology.
|
| 650 |
1 |
4 |
|a Biomedicine.
|
| 650 |
2 |
4 |
|a Neurosciences.
|
| 650 |
2 |
4 |
|a Pharmacology/Toxicology.
|
| 700 |
1 |
# |
|a Gombotz, Wayne.
|e editor.
|
| 700 |
1 |
# |
|a Bechtold-Peters, Karoline.
|e editor.
|
| 700 |
1 |
# |
|a Andya, James.
|e editor.
|
| 710 |
2 |
# |
|a SpringerLink (Online service)
|
| 773 |
0 |
# |
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9780387766423
|
| 830 |
# |
0 |
|a Biotechnology: Pharmaceutical Aspects ;
|v XI
|
| 856 |
4 |
0 |
|u https://ezaccess.library.uitm.edu.my/login?url=http://dx.doi.org/10.1007/978-0-387-76643-0
|
| 912 |
# |
# |
|a ZDB-2-SBL
|
| 950 |
# |
# |
|a Biomedical and Life Sciences (Springer-11642)
|